Yamada Y, Nohata N, Uchida A, et al. Replisome genes regulation by antitumor *miR‐101‐5p* in clear cell renal cell carcinoma. Cancer Sci. 2020;111:1392--1406. 10.1111/cas.14327

1. INTRODUCTION {#cas14327-sec-0001}
===============

Renal cell carcinoma (RCC) accounts for approximately 3% of adult malignancies and is the 12th most prevalent malignancy worldwide, with 338 000 newly diagnosed patients in 2012 and approximately 100 000 deaths annually.[1](#cas14327-bib-0001){ref-type="ref"} Clear cell RCC (ccRCC) is pathologically the most common type and accounts for approximately 75% of all cases.[2](#cas14327-bib-0002){ref-type="ref"} Although the prognosis is favorable with surgical resection for nonmetastatic RCC, approximately 20%‐30% of RCC patients have metastatic sites at the diagnosis and the 5‐year survival rate is less than 20%.[2](#cas14327-bib-0002){ref-type="ref"}, [3](#cas14327-bib-0003){ref-type="ref"} In addition, more than 20% of patients develop metastases during postoperative follow‐up periods.[4](#cas14327-bib-0004){ref-type="ref"} These clinical issues are caused by a lack of useful biomarkers for early detection of RCC and the inefficiency of therapy for patients with metastatic or treatment‐resistant RCC.

MicroRNAs (miRNAs) are classified as noncoding RNAs that are approximately 18‐25 bases in size. They are widely found, ranging from plants to humans.[5](#cas14327-bib-0005){ref-type="ref"} MicroRNAs bind to the 3′‐UTR of target genes and have many biological functions that are achieved by regulating the expression of protein‐coding genes in a sequence‐dependent manner.[6](#cas14327-bib-0006){ref-type="ref"} Numerous reports have indicated that miRNAs are closely involved in cell growth, migration, invasion, apoptosis, angiogenesis, and tumor metastasis in various human cancers.[7](#cas14327-bib-0007){ref-type="ref"} Interestingly, a single miRNA can regulate a vast number of protein‐coding or noncoding RNAs. Therefore, the analysis of aberrantly expressed miRNAs in human cancers provides us information about cancer‐modulating molecular networks.

Previously, we established a miRNA expression signature from autopsy samples of ccRCC patients who relapsed following sunitinib treatment.[8](#cas14327-bib-0008){ref-type="ref"} Based on this signature, we have identified a number of antitumor microRNAs (*miR‐101‐3p*, *miR‐455*‐duplex, and the *miR‐29‐*family) as well as the oncogenes that they control. All of the miRNAs were closely related to ccRCC development.[8](#cas14327-bib-0008){ref-type="ref"}, [9](#cas14327-bib-0009){ref-type="ref"}, [10](#cas14327-bib-0010){ref-type="ref"} The discovery of oncogenic networks mediated by antitumor miRNAs contributes to the elucidation of the molecular mechanisms mediating the pathogenesis of ccRCC.

Current RNA‐sequencing (‐seq) technology makes it possible to construct miRNA expression signatures in human cancer. Expressions of several passenger strands of miRNA are significantly up‐ or downregulated in cancer tissues from the miRNA signature.[11](#cas14327-bib-0011){ref-type="ref"}, [12](#cas14327-bib-0012){ref-type="ref"} Our functional assays showed that several passenger strands of miRNAs (eg, *miR‐455‐5p*, *miR‐144‐5p*, and *miR‐145‐3p*) had antitumor roles, as did the guide strands of miRNAs.[9](#cas14327-bib-0009){ref-type="ref"}, [11](#cas14327-bib-0011){ref-type="ref"}, [13](#cas14327-bib-0013){ref-type="ref"}, [14](#cas14327-bib-0014){ref-type="ref"}, [15](#cas14327-bib-0015){ref-type="ref"} In general, the passenger strand of miRNA is degraded and therefore considered to have no function.[16](#cas14327-bib-0016){ref-type="ref"} Our reports differ from the previous concept. Thus, we have discovered a new aspect of miRNA functionality.

Here, we focused on *miR‐101‐5p* (the passenger strand) to elucidate the function of *miR‐101‐5p* and determine its target oncogenes as useful diagnostic markers in ccRCC. Previous studies have shown that *miR‐101‐3p* (the guide strand of the *miR‐101* duplex) acts as an antitumor miRNA in several cancers by targeting oncogenic genes.[8](#cas14327-bib-0008){ref-type="ref"}, [17](#cas14327-bib-0017){ref-type="ref"} In contrast to *miR‐101‐3p*, the functional significance of *miR‐101‐5p* in cancer cells is poorly understood. Ectopic expression of *miR‐101‐5p* attenuated the aggressive phenotype of ccRCC cells. Downstream neighbor of son (*DONSON*) was directly regulated by *miR‐101‐5p*, and its aberrant expression was significantly associated with shorter survival in propensity score‐matched analysis. Moreover, several replisome genes controlled by *DONSON* and their expression were closely associated with ccRCC pathogenesis.

2. MATERIALS AND METHODS {#cas14327-sec-0002}
========================

2.1. Clinical samples and cell lines {#cas14327-sec-0003}
------------------------------------

In the present study, 18 clinical ccRCC tissue samples were obtained from patients received nephrectomy at Chiba University Hospital between 2014 and 2015 (Table [S1](#cas14327-sup-0009){ref-type="supplementary-material"}). Also, autopsy specimens were obtained from 5 patients whose disease was resistant to several tyrosine kinase inhibitor (TKI) treatments; samples were obtained from Teikyo University Chiba Medical Center Hospital between 2012 and 2016 (Table [S2](#cas14327-sup-0010){ref-type="supplementary-material"}). We obtained informed consent from all patients and the current research protocol was approved by the Institutional Review Board of Chiba University (acceptance no. 484). Two ccRCC cell lines (786‐0 and A498) from ATCC were used in this study. These cell lines were cultured in RPMI‐1640 with 10% FBS (HyClone).

2.2. Transfection of ccRCC cells with miRNAs, siRNAs, and plasmid vectors {#cas14327-sec-0004}
-------------------------------------------------------------------------

MicroRNAs, siRNAs, and vectors were transfected into cancer cells as described in our previous reports using the reagents listed in Table [S3](#cas14327-sup-0011){ref-type="supplementary-material"}.[18](#cas14327-bib-0018){ref-type="ref"}

2.3. RNA preparation and quantitative RT‐PCR {#cas14327-sec-0005}
--------------------------------------------

Total RNA including miRNA was isolated using TRIzol reagent (Invitrogen) in clinical specimens and ISOGEN reagent (Nippon Gene) in ccRCC cells.

TaqMan probes and *DONSON* primers were used and the reagents are listed in Table [S3](#cas14327-sup-0011){ref-type="supplementary-material"}. Quantitative RT‐PCR for *miR‐101‐5p* and *miR‐101‐3p* was used to validate miRNA expression. To normalize the data for analysis of mRNAs and miRNAs, *GUSB* and *RNU48* were used. The PCR quantification was carried out as previously described.[19](#cas14327-bib-0019){ref-type="ref"}, [20](#cas14327-bib-0020){ref-type="ref"}

2.4. Assays of proliferation, migration, and invasion {#cas14327-sec-0006}
-----------------------------------------------------

Cell proliferation, migration, and invasion were assessed as described previously.[19](#cas14327-bib-0019){ref-type="ref"}, [20](#cas14327-bib-0020){ref-type="ref"}

2.5. Assay of cell cycle {#cas14327-sec-0007}
------------------------

Clear cell RCC cells were transfected with either the transfection reagents alone as a control or *miR‐101‐5p*, *miR‐101‐3p*, and si‐*DONSON* in 6‐well tissue culture plates. Seventy‐two hours after transfection, these cells were harvested by trypsinization. Cells were stained with propidium iodide with the Cycletest Plus DNA Reagent Kit (BD Biosciences) and analyzed using the CyAn ADP analyzer (BD Biosciences). The proportion of cells in the G~0~/G~1~, S and G~2~/M phases were calculated and compared. We undertook each experiment in triplicate.

2.6. Assay of apoptosis {#cas14327-sec-0008}
-----------------------

In order to identify the apoptotic cells, the FITC Annexin V apoptosis detection kit (BD Biosciences) and the BD FACS Celesta flow cytometer (BD Biosciences) were used according to the manufacturer's instructions. We classified these cells as viable cells, dead cells, or early or late apoptotic cells and compared the percentage of apoptotic cells according to each condition. To evaluate apoptosis with western blotting, anti‐poly (ADP‐ribose) polymerase (PARP) was used. Adriamycin (ADM) was used as a positive control.

2.7. Incorporation of miR‐101‐5p and miR‐101‐3p into the RNA‐induced silencing complex by Ago2 immunoprecipitation {#cas14327-sec-0009}
------------------------------------------------------------------------------------------------------------------

After 72 hours, miRNAs incorporated into the RNA‐induced silencing complex (RISC) were isolated a human AGO2 miRNA isolation kit (Wako Pure Chemical Industries). The method of measuring the amount of *miR‐101‐5p* incorporated into RISC was according to a previous study.[14](#cas14327-bib-0014){ref-type="ref"}

2.8. Target genes regulated by miR‐101‐5p and miR‐101‐3p {#cas14327-sec-0010}
--------------------------------------------------------

Candidate target genes regulated by *miR‐101‐5p* or *miR‐101‐3p* were identified using in silico and genome‐wide gene expression analyses and those obtained from the TargetScan database (<http://www.targetscan.org/vert_70/>). Upregulated genes in RCC tissues compared with normal renal tissues were identified from public data in the Gene Expression Omnibus (GEO; accession no. GSE36895), from which we narrowed down these genes. Gene expression was analyzed with our oligo microarray data analyses (Human GE 60K; Agilent Technologies) that were deposited into the GEO (on 23 August 2018; <http://www.ncbi.nlm.nih.gov/geo/>) with accession number GSE118966.

2.9. Evaluation of miR‐101‐5p binding sites by luciferase reporter assay {#cas14327-sec-0011}
------------------------------------------------------------------------

The 3′‐UTR of *DONSON* and the 3′‐UTR lacking the putative *miR‐101‐5p* binding site (position 219‐225 in 3′‐UTR of *DONSON*) were cloned into the psiCHECk‐2 vector. A luciferase reporter assay was undertaken as previously described.[19](#cas14327-bib-0019){ref-type="ref"}, [20](#cas14327-bib-0020){ref-type="ref"}

2.10. Western blot analysis and immunohistochemistry {#cas14327-sec-0012}
----------------------------------------------------

Western blotting and immunohistochemistry (IHC) were carried out as described previously.[19](#cas14327-bib-0019){ref-type="ref"}, [20](#cas14327-bib-0020){ref-type="ref"} Primary Abs are listed in Table [S3](#cas14327-sup-0011){ref-type="supplementary-material"}. Tissue microarray (KD485S; Cosmo Bio) was used to show *DONSON* expression in normal kidney tissue with IHC.

2.11. Downstream genes of *DONSON* {#cas14327-sec-0013}
----------------------------------

To elucidate *DONSON*‐regulated pathways in ccRCC cells, we analyzed gene expression fluctuation in 786‐O cells transfected with si‐*DONSON*. Microarray data were used for expression signatures of si‐*DONSON* transfectants. The data were registered to the GEO on 4 December 2018 (accession no. GSE123317).

2.12. Clinical significance of miR‐101 and DONSON {#cas14327-sec-0014}
-------------------------------------------------

We examined the clinical importance of miRNAs and genes in RCC patients using the RNA‐seq database in The Cancer Genome Atlas (TCGA; <https://tcga-data.nci.nih.gov/tcga/>). Expression data and clinical information of these molecules were acquired from cBioPortal (<http://www.cbioportal.org/>) and the provisional data were downloaded on 8 January 2019.[21](#cas14327-bib-0021){ref-type="ref"}, [22](#cas14327-bib-0022){ref-type="ref"}, [23](#cas14327-bib-0023){ref-type="ref"} We calculated the *Z* scores as the mRNA expression values. Gene Set Enrichment Analysis (GSEA) was undertaken based on mRNA‐seq data from cBioPortal. A heatmap of gene expression was provided by the RCC‐RNA‐seq database.

2.13. Statistical analyses {#cas14327-sec-0015}
--------------------------

The Mann‐Whitney *U* test was applied to compare between 2 groups. For multiple groups, one‐way ANOVA and Tukey tests for post‐hoc analyses was applied. These analyses were carried out with GraphPad Prism7 (GraphPad Software) and JMP Pro 14 (SAS Institute). Expert StatView (version 5; SAS Institute) was used for other analyses.

3. RESULTS {#cas14327-sec-0016}
==========

3.1. Analysis of miR‐101‐5p and miR‐101‐3p expression levels in clinical ccRCC tissues and their clinical significance {#cas14327-sec-0017}
----------------------------------------------------------------------------------------------------------------------

In the human genome, the chromosomal location of *miR‐101* is at 1q31.3. The mature sequences of *miR‐101‐5p* and *miR‐101‐3p* are 5′‐CAGUUAUCACAGUGCUGAUGCU‐3′ and 5′‐UACAGUACUGUGAUAACUGAA‐3′, respectively. Both *miR‐101‐5p* and *miR‐101‐3p* expressions were significantly reduced in ccRCC tissues compared with those in adjacent noncancerous tissues (*P* = .027 and *P* = .0057, respectively; Figure [1](#cas14327-fig-0001){ref-type="fig"}A,B). In addition, Spearman's rank analysis showed strong positive correlation between *miR‐101‐5p* and *miR‐101‐3p* expression levels (*R* = 0.943, *P* \< .0001; Figure [1](#cas14327-fig-0001){ref-type="fig"}C). From a large cohort of TCGA database, low expressions of *miR‐101‐5p* and *miR‐101‐3p* were significantly associated with high pathological grade (both, *P* \< .0001; Figure [1](#cas14327-fig-0001){ref-type="fig"}D,E) and poor clinical outcomes (disease‐free survival, *P* = .0485 and *P* = .0457; overall survival, *P* = .0397 and *P* = .00271, respectively, Figure [1](#cas14327-fig-0001){ref-type="fig"}F‐I) in ccRCC patients.

![Expression of *miR‐101* and its clinical significance in clear cell renal cell carcinoma (ccRCC). A‐C, Expression levels of *miR‐101‐5p* and *miR‐101‐3p* in ccRCC clinical specimens. *RNU48* was used as an internal control. Expression levels of *miR‐101‐5p* and *miR‐101‐3p* were positively correlated by Spearman's rank test. D, E, Based on The Cancer Genome Atlas database, high grades of RCC were significantly associated with low *miR‐101* expression levels. F‐I, Low expression levels of *miR‐101* were significantly associated with poor prognosis in RCC patients (disease‐free survival and overall survival). RNA‐seq, RNA sequencing; RSEM, RNA sequencing by expectation‐maximization](CAS-111-1392-g001){#cas14327-fig-0001}

3.2. Antitumor functions of miR‐101‐5p and miR‐101‐3p in ccRCC cells {#cas14327-sec-0018}
--------------------------------------------------------------------

Restoration of *miR‐101‐5p* and *miR‐101‐3p* expression indicated that both miRNAs significantly suppressed cancer cell proliferation (Figure [2](#cas14327-fig-0002){ref-type="fig"}A), migration (Figure S1A,B) and invasion potentials (Figure S1C,D).

![Functional analysis of *miR‐101*‐duplex in clear cell renal cell carcinoma cells. A, Cell proliferation after introduction of the *miR‐101*‐duplex. B‐D, Effect of *miR‐101* on apoptosis, as assessed by apoptosis assays and western blot analysis of cleaved poly (ADP‐ribose) polymerase (PARP), as a marker of apoptosis. *GAPDH* was used as the loading control. Adriamycin (ADM) was used as a positive control. E, Effect of *miR‐101* on the cell cycle. Flow cytometric analyses of cell‐cycle‐phase distribution in control cells and cells transfected with the *miR‐101*. Bar charts represent the percentages of inhibitor‐transfected cells relative to the control cells in the G~0~/G~1~, S, G~2~/M, and sub‐G~1~ phases, respectively. \**P* \< .0001](CAS-111-1392-g002){#cas14327-fig-0002}

Furthermore, the apoptotic rate was elevated in *miR‐101‐5p* and *miR‐101‐3p* transfected cells compared to controls (Figure [2](#cas14327-fig-0002){ref-type="fig"}B,C). In addition, transfection of *miR‐101‐3p* apparently upregulated cleaved PARP expression (Figure [2](#cas14327-fig-0002){ref-type="fig"}D). In cell cycle analyses, ectopic expression of these miRNAs confirmed increase in the sub‐G~1~ peak in ccRCC cells (Figure [2](#cas14327-fig-0002){ref-type="fig"}E). We analyzed the expression levels of cell cycle‐related genes by ectopic expression of *miR‐101‐5p* and/or *miR‐101‐3p* in ccRCC cells (Table [S4](#cas14327-sup-0012){ref-type="supplementary-material"}). Downregulation of *CCNB1*, *CDK1*, *CDK2*, and *CDK4* were detected by microarray data.

Cell migration and invasive abilities were significantly inhibited by ectopic expression of *miR‐101‐5p* and *miR‐101‐3p* in ccRCC cells. To explain this phenomenon, the expression of epithelial‐mesenchymal transition (EMT)‐related genes was examined by microarray analyses (Table [S4](#cas14327-sup-0012){ref-type="supplementary-material"}). The mRNA expression levels of *CDH2*, *VIM*, *ZEB1*, *TWIST1*, *SNAI1*, and *FN1* were reduced by *miR‐101‐5p* and/or *miR‐101‐3p* transfection into ccRCC cells. Furthermore, we investigated the expression changes of EMT‐related proteins (eg, E‐cadherin, N‐cadherin, SLUG, Vimentin, and TWIST) by ectopic expression of *miR‐101‐5p* and *miR‐101‐3p* in ccRCC cells (Figure S2). Notably, the expression levels of N‐cadherin, SLUG, and Vimentin were suppressed by expressions of *miR‐101‐5p* and *miR‐101‐3p* in 2 RCC cell lines, 786‐O and A498 (Figure S2). Downregulation of TWIST was detected in 786‐O cells by *miR‐101‐5p* expression. Our present data indicated that expression of these miRNAs regulate the expression of EMT‐related proteins and they play critical roles in malignant transformation of ccRCC cells.

In addition, we examined the synergistic effect of the 2 miRNAs on cell proliferation, apoptosis, and the cell cycle. No synergistic effect of antitumor effects in RCC cells by the ectopic expression of the 2 miRNAs, *miR‐101‐5p* and *miR‐101‐3p*, was observed (Figure S3).

3.3. Incorporation of miR‐101‐5p into RISC in ccRCC cells {#cas14327-sec-0019}
---------------------------------------------------------

To verify that *miR‐101‐5p* (passenger strand) had actual functions in ccRCC cells, it is essential that miRNAs are incorporated into the RISC to control target genes. Immunoprecipitation using anti‐Ago2 Abs was carried out after transfection of *miR‐101‐5p* into 786‐O cells. The amount of *miR‐101‐5p* incorporated into the protein was measured by PCR. Levels of *miR‐101‐5p* in the immunoprecipitation were much higher than those in mock, miR‐control, or *miR‐101‐3p*‐transfected cells (*P* \< .0001; Figure S4).

3.4. Candidate target genes of miR‐101‐5p and miR‐101‐3p {#cas14327-sec-0020}
--------------------------------------------------------

We identified genes that had putative target sites for *miR‐101* in their 3′‐UTR and that showed downregulated expression in ccRCC cells transfected with *miR‐101* (log~2~ ratio less than −1.5) and upregulated expression levels (fold‐change greater than 1.5) in RCC tissues from the GEO database (Figure [3](#cas14327-fig-0003){ref-type="fig"}A). Using this search strategy, 38 and 47 genes were found as candidate target genes for *miR‐101‐5p* and *miR‐101‐3p,* respectively (Table [1](#cas14327-tbl-0001){ref-type="table"}). Among these genes, we focused on *DONSON*, which is targeted by *miR‐101‐5p* and had the strongest relation to the prognosis from TCGA database.

![*miR‐101‐5p* candidate target gene and its clinical significance. A, Strategy for searching for oncogenes targeted by *miR‐101‐5p* in clear cell renal cell carcinoma (ccRCC). B, *DONSON* mRNA expression levels 48 h after transfection of ccRCC cells with 10 nM *miR‐101‐5p* or *miR‐101‐3p*. *GAPDH* was used as an internal control. C, Protein expression of DONSON 72 h after transfection with *miR‐101‐5p* or *miR‐101‐3p*. GAPDH was used as a loading control. D, E, Dual luciferase reporter assays with vectors encoding the putative *miR‐101‐5p* target site in the WT *DONSON* 3′‐UTR and a 3′‐UTR with the target sites deleted (deletion‐type (DT)). Normalized data were calculated as the ratio of *Renilla*/firefly luciferase activities. F, G, Kaplan‐Meier analyses for overall survival in the entire cohort and propensity score‐matched cohort. Patients were divided into 2 groups according to *DONSON* expression levels: high expression (red line) and low expression (blue line). H, Multivariate analysis of overall survival with clinical parameters, including *DONSON* expression. I, *DONSON* mRNA expression levels in normal, primary (sunitinib‐naïve) ccRCC and sunitinib‐treated ccRCC patients. J‐L, Immunostaining showed the expression of DONSON in normal kidney tissue, primary ccRCC, and sunitinib‐treated ccRCC (100× and 400× magnification fields). \**P* \< .0001; \*\**P* \< .005; \*\*\**P* \< .01. CI, confidence interval; GEO, Gene Expression Omnibus; TCGA, The Cancer Genome Atlas](CAS-111-1392-g003){#cas14327-fig-0003}

###### 

*miR‐101*‐duplex regulatory genes in clear cell renal cell carcinoma cells

  Gene symbol       Gene name                                                                               Entrez Gene ID   Cytoband       GEO expression fold‐change (tumor/normal)   Mock vs miR‐101‐5p transfection in 786‐O cells (log2 ratio)   OS analysis from TCGA database (high vs low expression, *P* value)
  ----------------- --------------------------------------------------------------------------------------- ---------------- -------------- ------------------------------------------- ------------------------------------------------------------- --------------------------------------------------------------------
  (A)*miR‐101‐5p*                                                                                                                                                                                                                                     
  *DONSON*          Downstream neighbor of SON                                                              29980            hs\|21q22.11   1.665                                       −1.952                                                        8.10E‐15
  *EFHD2*           EF‐hand domain family, member D2                                                        79180            hs\|1p36.21    2.000                                       −1.933                                                        1.16E‐05
  *NAP1L1*          Nucleosome assembly protein 1‐like 1                                                    4673             hs\|12q21.2    1.536                                       −1.672                                                        1.40E‐05
  *HSPA6*           Heat shock 70 kDa protein 6 (HSP70B\')                                                  3310             hs\|1q23.3     2.814                                       −1.509                                                        0.000116
  *PBK*             PDZ binding kinase                                                                      55872            hs\|8p21.1     2.982                                       −2.425                                                        0.0018800
  *DPYSL3*          Dihydropyrimidinase‐like 3                                                              1809             hs\|5q32       2.327                                       −1.548                                                        0.0038900
  *EVI2A*           Ecotropic viral integration site 2A                                                     2123             hs\|17q11.2    2.971                                       −1.682                                                        0.0073700
  *KIAA1841*        KIAA1841                                                                                84542            hs\|2p15       2.132                                       −1.658                                                        0.0106000
  *SNX10*           Sorting nexin 10                                                                        29887            hs\|7p15.2     1.564                                       −2.843                                                        0.0112000
  *GINS1*           GINS complex subunit 1 (Psf1 homolog)                                                   9837             hs\|20p11.21   1.532                                       −2.077                                                        0.0137000
  *LYSMD2*          LysM, putative peptidoglycan‐binding, domain containing 2                               256586           hs\|15q21.2    1.433                                       −1.687                                                        0.0244000
  *TBL1XR1*         Transducin (beta)‐like 1 X‐linked receptor 1                                            79718            hs\|3q26.32    1.427                                       −1.879                                                        0.0396000
  *KCND2*           Potassium voltage‐gated channel, Shal‐related subfamily, member 2                       3751             hs\|7q31.31    2.588                                       −1.551                                                        0.0444000
  *ITGA5*           Integrin, alpha 5 (fibronectin receptor, alpha polypeptide)                             3678             hs\|12q13.13   7.156                                       −1.932                                                        0.0818000
  *MEGF6*           Multiple EGF‐like‐domains 6                                                             1953             hs\|1p36.32    2.113                                       −1.608                                                        0.1510000
  *KDELC2*          KDEL (Lys‐Asp‐Glu‐Leu) containing 2                                                     143888           hs\|11q22.3    1.710                                       −1.651                                                        0.1690000
  *CD109*           CD109 molecule                                                                          135228           hs\|6q13       1.449                                       −1.739                                                        0.2230000
  *MET*             Met proto‐oncogene                                                                      4233             hs\|7q31.2     2.553                                       −2.159                                                        0.2240000
  *HAUS6*           HAUS augmin‐like complex, subunit 6                                                     54801            hs\|9p22.1     1.831                                       −2.069                                                        0.2980000
  *FCHSD2*          FCH and double SH3 domains 2                                                            9873             hs\|11q13.4    1.482                                       −1.645                                                        0.3190000
  *QSER1*           Glutamine and serine rich 1                                                             79832            hs\|11p13      1.565                                       −2.025                                                        0.3800000
  *NCAPG2*          Non‐SMC condensin II complex, subunit G2                                                54892            hs\|7q36.3     2.127                                       −2.679                                                        0.3850000
  *MEF2C*           Myocyte enhancer factor 2C                                                              4208             hs\|5q14.3     2.693                                       −1.988                                                        0.4720000
  *PMP22*           Peripheral myelin protein 22                                                            5376             hs\|17p12      3.152                                       −1.938                                                        0.4800000
  *METAP1D*         Methionyl aminopeptidase type 1D (mitochondrial)                                        254042           hs\|2q31.1     1.492                                       −1.645                                                        0.4810000
  *IL16*            Interleukin 16                                                                          3603             hs\|15q25.1    1.799                                       −1.642                                                        0.6600000
  *EGLN3*           Egl‐9 family hypoxia‐inducible factor 3                                                 112399           hs\|14q13.1    13.669                                      −1.568                                                        0.6880000
  *CKAP2*           Cytoskeleton associated protein 2                                                       26586            hs\|13q14.3    1.454                                       −1.803                                                        0.8310000
  *PCSK5*           Proprotein convertase subtilisin/kexin type 5                                           5125             hs\|9q21.13    1.490                                       −2.535                                                        0.0000246[a](#cas14327-note-0002){ref-type="fn"}
  *MXI1*            MAX interactor 1, dimerization protein                                                  4601             hs\|10q25.2    1.987                                       −2.013                                                        0.0000979[a](#cas14327-note-0002){ref-type="fn"}
  *KCTD20*          Potassium channel tetramerization domain containing 20                                  222658           hs\|6p21.31    1.415                                       −1.582                                                        0.0006140[a](#cas14327-note-0002){ref-type="fn"}
  *LRRC8C*          Leucine rich repeat containing 8 family, member C                                       84230            hs\|1p22.2     1.890                                       −1.593                                                        0.0039200[a](#cas14327-note-0002){ref-type="fn"}
  *RCBTB2*          Regulator of chromosome condensation (RCC1) and BTB (POZ) domain containing protein 2   1102             hs\|13q14.2    1.456                                       −2.255                                                        0.0054900[a](#cas14327-note-0002){ref-type="fn"}
  *EDIL3*           EGF‐like repeats and discoidin I‐like domains 3                                         10085            hs\|5q14.3     2.902                                       −2.611                                                        0.0085400[a](#cas14327-note-0002){ref-type="fn"}
  *TPR*             Translocated promoter region, nuclear basket protein                                    7175             hs\|1q31.1     1.663                                       −1.630                                                        0.0124000[a](#cas14327-note-0002){ref-type="fn"}
  *NR3C1*           Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)               2908             hs\|5q31.3     2.111                                       −1.718                                                        0.0178000[a](#cas14327-note-0002){ref-type="fn"}
  *STARD13*         StAR‐related lipid transfer (START) domain containing 13                                90627            hs\|13q13.1    1.445                                       −2.355                                                        0.0374000[a](#cas14327-note-0002){ref-type="fn"}
  *SETD7*           SET domain containing (lysine methyltransferase) 7                                      80854            hs\|4q31.1     2.225                                       −2.392                                                        0.0459000[a](#cas14327-note-0002){ref-type="fn"}

  Gene symbol       Gene name                                                                              Entrez Gene ID   Cytoband       GEO expression fold‐change (tumor/normal)   Mock vs miR‐101‐3p transfection in 786‐O cells (log2 ratio)   OS analysis from TCGA database (high vs low expression, *P* value)
  ----------------- -------------------------------------------------------------------------------------- ---------------- -------------- ------------------------------------------- ------------------------------------------------------------- --------------------------------------------------------------------
  (B)*miR‐101‐3p*                                                                                                                                                                                                                                    
  *JAK3*            Janus kinase 3                                                                         3718             hs\|19p13.11   2.283                                       −1.516                                                        1.23E‐09
  *MX2*             Myxovirus (influenza virus) resistance 2 (mouse)                                       4600             hs\|21q22.3    1.508                                       −1.830                                                        3.81E‐08
  *NAP1L1*          Nucleosome assembly protein 1‐like 1                                                   4673             hs\|12q21.2    1.536                                       −1.795                                                        1.40E‐05
  *TMEM39B*         Transmembrane protein 39B                                                              55116            hs\|1p35.1     2.416                                       −1.037                                                        2.64E‐05
  *ANXA2*           Annexin A2                                                                             302              hs\|15q22.2    1.659                                       −1.811                                                        0.000151
  *STIL*            SCL/TAL1 interrupting locus                                                            6491             hs\|1p33       2.136                                       −1.176                                                        0.000255
  *FBXO32*          F‐box protein 32                                                                       114907           hs\|8q24.13    1.485                                       −1.079                                                        0.000574
  *LMNB1*           Lamin B1                                                                               4001             hs\|5q23.2     2.245                                       −3.395                                                        0.002780
  *AP3S1*           Adaptor‐related protein complex 3, sigma 1 subunit                                     1176             hs\|5q23.1     1.622                                       −1.320                                                        0.022000
  *SELPLG*          Selectin P ligand                                                                      6404             hs\|12q24.11   2.757                                       −1.457                                                        0.026600
  *RASD2*           RASD family, member 2                                                                  23551            hs\|22q12.3    2.707                                       −1.957                                                        0.080900
  *NAV1*            Neuron navigator 1                                                                     89796            hs\|1q32.1     2.247                                       −1.055                                                        0.086600
  *MAD2L1*          MAD2 mitotic arrest deficient‐like 1 (yeast)                                           4085             hs\|4q27       1.954                                       −1.418                                                        0.092900
  *TTYH2*           Tweety family member 2                                                                 94015            hs\|17q25.1    1.958                                       −1.103                                                        0.097200
  *DDIT4*           DNA‐damage‐inducible transcript 4                                                      54541            hs\|10q22.1    3.996                                       −1.103                                                        0.148000
  *IKZF3*           IKAROS family zinc finger 3 (Aiolos)                                                   22806            hs\|17q12      2.099                                       −1.098                                                        0.165000
  *RRM1*            Ribonucleotide reductase M1                                                            6240             hs\|11p15.4    1.836                                       −1.294                                                        0.173000
  *NETO2*           Neuropilin (NRP) and tolloid (TLL)‐like 2                                              81831            hs\|16q12.1    10.418                                      −1.545                                                        0.191000
  *IKZF2*           IKAROS family zinc finger 2 (Helios)                                                   22807            hs\|2q34       1.499                                       −2.151                                                        0.221000
  *ZCCHC2*          Zinc finger, CCHC domain containing 2                                                  54877            hs\|18q21.33   2.171                                       −1.391                                                        0.247000
  *CEBPA*           CCAAT/enhancer binding protein (C/EBP), alpha                                          1050             hs\|19q13.11   1.531                                       −1.176                                                        0.320000
  *ITGA3*           Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA‐3 receptor)                   3675             hs\|17q21.33   1.486                                       −1.224                                                        0.325000
  *CPNE8*           Copine VIII                                                                            144402           hs\|12q12      1.513                                       −1.306                                                        0.352000
  *STAT1*           Signal transducer and activator of transcription 1, 91kDa                              6772             hs\|2q32.2     1.550                                       −1.047                                                        0.376000
  *STC2*            Stanniocalcin 2                                                                        8614             hs\|5q35.1     6.507                                       −1.152                                                        0.440000
  *NCF2*            Neutrophil cytosolic factor 2                                                          4688             hs\|1q25.3     3.432                                       −1.545                                                        0.495000
  *ZNF532*          Zinc finger protein 532                                                                55205            hs\|18q21.32   1.899                                       −1.237                                                        0.504000
  *FAM78A*          Family with sequence similarity 78, member A                                           286336           hs\|9q34.13    4.577                                       −1.504                                                        0.534000
  *BAZ2A*           Bromodomain adjacent to zinc finger domain, 2A                                         11176            hs\|12q13.3    1.700                                       −1.433                                                        0.739000
  *MCTP1*           Multiple C2 domains, transmembrane 1                                                   79772            hs\|5q15       3.092                                       −1.720                                                        0.749000
  *RAB27A*          RAB27A, member RAS oncogene family                                                     5873             hs\|15q21.3    1.452                                       −1.602                                                        0.766000
  *CARD8*           Caspase recruitment domain family, member 8                                            22900            hs\|19q13.33   1.650                                       −1.535                                                        0.854000
  *RPS6KA5*         Ribosomal protein S6 kinase, 90kDa, polypeptide 5                                      9252             hs\|14q32.11   1.480                                       −1.155                                                        6.28E‐06[a](#cas14327-note-0002){ref-type="fn"}
  *PCSK5*           Proprotein convertase subtilisin/kexin type 5                                          5125             hs\|9q21.13    1.490                                       −1.503                                                        2.46E‐05[a](#cas14327-note-0002){ref-type="fn"}
  *ZNF792*          Zinc finger protein 792                                                                126375           hs\|19q13.11   1.534                                       −1.348                                                        0.000156[a](#cas14327-note-0002){ref-type="fn"}
  *TGFA*            transforming growth factor, alpha                                                      7039             hs\|2p13.3     2.497                                       −1.122                                                        0.000477[a](#cas14327-note-0002){ref-type="fn"}
  *NRP1*            Neuropilin 1                                                                           8829             hs\|10p11.22   1.509                                       −1.199                                                        0.001140[a](#cas14327-note-0002){ref-type="fn"}
  *SPRY1*           Sprouty homolog 1, antagonist of FGF signaling (Drosophila)                            10252            hs\|4q28.1     1.622                                       −1.125                                                        0.003680[a](#cas14327-note-0002){ref-type="fn"}
  *CDH5*            Cadherin 5, type 2 (vascular endothelium)                                              1003             hs\|16q21      2.616                                       −1.448                                                        0.009350[a](#cas14327-note-0002){ref-type="fn"}
  *ICK*             Intestinal cell (MAK‐like) kinase                                                      22858            hs\|6p12.2     1.619                                       −1.514                                                        0.011900[a](#cas14327-note-0002){ref-type="fn"}
  *CDK19*           Cyclin‐dependent kinase 19                                                             23097            hs\|6q21       2.174                                       −1.108                                                        0.016600[a](#cas14327-note-0002){ref-type="fn"}
  *NAA15*           N(alpha)‐acetyltransferase 15, NatA auxiliary subunit                                  80155            hs\|4q31.1     1.460                                       −2.003                                                        0.020100[a](#cas14327-note-0002){ref-type="fn"}
  *MLEC*            Malectin                                                                               9761             hs\|12q24.31   1.519                                       −1.385                                                        0.020400[a](#cas14327-note-0002){ref-type="fn"}
  *BDP1*            B double prime 1, subunit of RNA polymerase III transcription initiation factor IIIB   55814            hs\|5q13.2     1.448                                       −1.272                                                        0.021800[a](#cas14327-note-0002){ref-type="fn"}
  *CBL*             Cbl proto‐oncogene, E3 ubiquitin protein ligase                                        867              hs\|11q23.3    1.800                                       −1.027                                                        0.051800[a](#cas14327-note-0002){ref-type="fn"}
  *EMP1*            Epithelial membrane protein 1                                                          2012             hs\|12p13.1    1.615                                       −1.521                                                        0.059700[a](#cas14327-note-0002){ref-type="fn"}
  *KDM5A*           Lysine (K)‐specific demethylase 5A                                                     5927             hs\|12p13.33   1.862                                       −1.000                                                        0.074900[a](#cas14327-note-0002){ref-type="fn"}

GEO, Gene Expression Omnibus; miR, microRNA; OS, overall survival; RCC, renal cell carcinoma; TCGA, The Cancer Genome Atlas.

^a^Poor prognosis in patients with low gene expression.

John Wiley & Sons, Ltd

3.5. MicroRNA‐101‐5p targeted *DONSON* expression {#cas14327-sec-0021}
-------------------------------------------------

mRNA and protein levels of DONSON were significantly reduced after transfection of 786‐0 and A498 cells with *miR‐101‐5p* compared to control cells (Figure [3](#cas14327-fig-0003){ref-type="fig"}B,C).

The TargetScan Human database showed that there is a binding site for *miR‐101‐5p* (positions 219‐225) in the *DONSON* 3′‐UTR (Figure [3](#cas14327-fig-0003){ref-type="fig"}D). A luciferase reporter assay was carried out using vectors containing these sequences to see if *miR‐101‐5p* directly regulates DONSON expression depending on the sequence. Cotransfection of *miR‐101‐5p* with vectors significantly suppressed luciferase activity compared to control cells (*P* = .0012) (Figure [3](#cas14327-fig-0003){ref-type="fig"}E).

3.6. Clinical significance of *DONSON* expression in RCC patients {#cas14327-sec-0022}
-----------------------------------------------------------------

Conventional and propensity score‐matched cohort analyses showed that patients with high *DONSON* expression showed poor prognosis (Figure [3](#cas14327-fig-0003){ref-type="fig"}F,G). The clinical background of the patients used for analysis is shown in Table [S5](#cas14327-sup-0013){ref-type="supplementary-material"}. Furthermore, multivariate analysis has shown that gene expression is an independent prognostic factor (Figure [3](#cas14327-fig-0003){ref-type="fig"}H).

Combination analyses (*miR‐101‐5p* and *DONSON*) showed that patient group (low expression of *miR‐101‐5p* or high expression of *DONSON*) was a promising prognostic marker of patients with RCC (disease‐free survival, *P* \< .001; overall survival, *P* \< .001) (Figure S5A,B). High expression of *DONSON* was involved in RCC pathogenesis, eg, tumor stage, metastasis, and grade (Figure S5C‐G).

3.7. Expression of DONSON in sunitinib‐naïve and sunitinib‐treated specimens {#cas14327-sec-0023}
----------------------------------------------------------------------------

*DONSON* mRNA expression levels were significantly elevated in primary ccRCC tissues compared with those in adjacent noncancerous tissues (*P* = .0051) (Figure [3](#cas14327-fig-0003){ref-type="fig"}I). Furthermore, the expression levels in sunitinib‐treated ccRCC tissues were highly expressed compared with those in primary ccRCC tissues (*P* \< .0001) (Figure [3](#cas14327-fig-0003){ref-type="fig"}I).

In IHC staining, the expression of *DONSON* was gradually increased in the order of normal tissue, primary (sunitinib‐naïve) RCC and sunitinib‐treated ccRCC (Figure [3](#cas14327-fig-0003){ref-type="fig"}J‐L).

3.8. Knockdown assay and rescue study of DONSON in ccRCC cells {#cas14327-sec-0024}
--------------------------------------------------------------

We confirmed that the expression levels of both *DONSON* mRNA and DONSON protein could be suppressed by si‐*DONSON* transfection of ccRCC cells (Figure S6A,B). Downregulation of *DONSON* with siRNAs significantly attenuated cell proliferation (Figure [4](#cas14327-fig-0004){ref-type="fig"}A), migration and invasive potentials (Figure S6C,D).

![*DONSON* knockdown assay by siRNA and the effect of cotransfection of *DONSON*/*miR‐101‐5p*. A, Cell proliferation activity after si‐*DONSON* transfection into clear cell renal cell carcinoma ccRCC cells. B, Cell proliferation 72 h after reverse transfection with *miR‐101‐5p* and 48 h after forward transfection with the *DONSON* vector. C, Cell migration 48 h after reverse transfection with *miR‐101‐5p* and 24 h after forward transfection with the *DONSON* vector. D, Cell invasion 48 h after reverse transfection with *miR‐101‐5p* and 24 h after forward transfection with *DONSON* vector. E‐G, Effects of si‐*DONSON* on apoptosis, as assessed by apoptosis assays and western blot analysis of cleaved poly (ADP‐ribose) polymerase (PARP), a marker of apoptosis. GAPDH was used as the loading control. Adriamycin (ADM) was used as a positive control. H, Effect of si‐*DONSON* on the cell cycle. Flow cytometric analyses of cell‐cycle‐phase distributions in control cells and cells transfected with si‐*DONSON*. Bar charts represent the percentages of si‐*DONSON*‐transfected cells relative to the control cells in the G~0~/G~1~, S, and G~2~/M phases, respectively. \**P* \< .0001; \*\**P* \< .005](CAS-111-1392-g004){#cas14327-fig-0004}

In addition, introduction of both *DONSON* and *miR‐101‐5p* significantly restored cell proliferation, migration, and invasive activity, compared to cells transfected with *miR‐101‐5p* alone (Figure [4](#cas14327-fig-0004){ref-type="fig"}B‐D). We confirmed that *DONSON* and *miR‐101‐5p* transfection restored DONSON protein expression (Figure S7).

Furthermore, the proportion of apoptotic cells was elevated in si‐*DONSON*‐transfected cells compared to control cells (Figure [4](#cas14327-fig-0004){ref-type="fig"}E,F). Transfection of si‐*DONSON* did not apparently upregulate the level of cleaved PARP (Figure [4](#cas14327-fig-0004){ref-type="fig"}G). In cell cycle assays, the number of cells in the G~2~/M phase were significantly elevated in si‐*DONSON* transfected cells than control cells (Figure [4](#cas14327-fig-0004){ref-type="fig"}H).

3.9. *DONSON* expression analyses combining clinical database and in vitro experiments {#cas14327-sec-0025}
--------------------------------------------------------------------------------------

We identified differentially expressed genes that had similar expression behaviors to that of *DONSON* (Figure [5](#cas14327-fig-0005){ref-type="fig"}A). The GSEA showed that the top signaling pathway that was enriched in *DONSON* high RCC patients was the G~2~/M checkpoint (Figure [5](#cas14327-fig-0005){ref-type="fig"}B). Furthermore, using the Kyoto Encyclopedia of Genes and Genomes pathways analysis, we found that the top significantly enriched pathway in 992 genes that had similar expression behavior to that of *DONSON* was DNA replication (Figure [5](#cas14327-fig-0005){ref-type="fig"}C,D). A heatmap visualization of gene expression of DNA replication pathway‐related genes is shown in Figure [5](#cas14327-fig-0005){ref-type="fig"}E. Most of the genes coexpressed with *DONSON* were significantly associated with prognosis in ccRCC patients (Figure S8).

![The Cancer Genome Atlas (TCGA) database analysis of clinical significance and function of *DONSON* in clear cell renal cell carcinoma. A, Identification of differentially expressed genes in the *DONSON* high group and the si‐*DONSON* group. B, Gene Set Enrichment Analysis (GSEA) of mRNA expression levels of *DONSON* high RCC patients. C, Venn diagram showed the overlapped 992 genes among TCGA and RNAi. D, Significantly enriched pathways including 992 genes that showed similar expression behaviors with *DONSON* using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways analysis. E, Heatmap visualization of gene expression of DNA replication pathway‐related genes](CAS-111-1392-g005){#cas14327-fig-0005}

3.10. Downstream genes mediated by *DONSON* in ccRCC cells {#cas14327-sec-0026}
----------------------------------------------------------

After microarray analysis, we identified 50 genes that were downregulated (log~2~ \<−1.0) after transfection with si‐*DONSON* (Table [S6](#cas14327-sup-0014){ref-type="supplementary-material"}). *DONSON* expression was the most downregulated after si‐*DONSON* transfection, indicating that these analyses were reliable and can be analyzed.

4. DISCUSSION {#cas14327-sec-0027}
=============

A remarkable property of miRNA is that a single miRNA species can control a huge number of RNA transcripts under normal and pathologic conditions.[5](#cas14327-bib-0005){ref-type="ref"} Therefore, miRNA‐controlled intracellular RNA networks are being investigated in cancer cells. From RNA‐seq‐based miRNA signatures, some passenger strands of miRNAs, eg, *miR‐144‐5p*, *miR‐455‐5p*, and *miR‐532‐3p*, possess antitumor activity in ccRCC cells and their target genes contributed to its pathogenesis.[9](#cas14327-bib-0009){ref-type="ref"}, [14](#cas14327-bib-0014){ref-type="ref"}, [24](#cas14327-bib-0024){ref-type="ref"} Passenger strands of miRNAs are generally not examined. Therefore, characterization of miRNA passenger strands in cancer regulatory networks is important for the development of novel diagnostic approaches.

In this study, we focused on *miR‐101‐5p* (the passenger strand of pre‐*miR‐101*) and investigated the associated regulatory RNA networks in ccRCC cells. Previous studies of *miR‐101‐3p* (the guide strand of pre‐*miR‐101*) found that it was often downregulated in a wide range of human cancers and acted as an antitumor miRNA through its targeting of several oncogenes.[17](#cas14327-bib-0017){ref-type="ref"} Our miRNA signature of patients with sunitinib failure showed that *miR‐101‐5p* was the most downregulated miRNA in cancer tissues. Moreover, ectopic expression of miR‐101‐3p significantly blocked the aggressive phenotype.[8](#cas14327-bib-0008){ref-type="ref"} Direct control of enhancer of zeste homolog 2 (*EZH2*), which functions as an oncogene in various cancers, has been proven in many studies.[25](#cas14327-bib-0025){ref-type="ref"} Our previous study showed that antitumor *miR‐101‐3p* directly regulated ubiquitin like with phd and ring finger domains 1 (*UHRF1*) in ccRCC cells.[8](#cas14327-bib-0008){ref-type="ref"} Aberrant expression of *UHRF1* was observed in several cancers and its overexpression facilitated cancer cell malignancy.[26](#cas14327-bib-0026){ref-type="ref"} In contrast to those studies of *miR‐101‐3p*, investigation of *miR‐101‐5p* has rarely been undertaken.

In a few reports, *miR‐101‐5p* expression was found to be downregulated. *miR‐101‐5p* was shown to inhibit cell aggressiveness through targeting of C‐X‐C motif chemokine ligand 6 (*CXCL6*) in cervical cancer and nonsmall‐cell lung carcinoma.[27](#cas14327-bib-0027){ref-type="ref"}, [28](#cas14327-bib-0028){ref-type="ref"} To our knowledge, the present study is the first report to show the antitumor functions of *miR‐101‐5p* in ccRCC. The elucidation of *miR‐101‐5p*‐controlled novel oncogenic networks in ccRCC cells is particularly important.

In further analysis of *miR‐101‐5p* in ccRCC, we identified candidate target oncogenes using genome‐wide expression analysis. A total of 38 oncogenes was found to be regulated by *miR‐101‐5p*. Of these oncogenic targets, the high expression of 13 genes was a significant prognostic factor for ccRCC. We focused on *DONSON* because it was directly regulated by *miR‐101‐5p* and it was the best predictor of poor prognosis of patients. Recently, *DONSON* was found to encode a novel fork protein factor and play an important role in mammalian DNA replication and genome stability. Moreover, its mutation caused microcephalic dwarfism.[29](#cas14327-bib-0029){ref-type="ref"}, [30](#cas14327-bib-0030){ref-type="ref"}, [31](#cas14327-bib-0031){ref-type="ref"}, [32](#cas14327-bib-0032){ref-type="ref"}, [33](#cas14327-bib-0033){ref-type="ref"} Previous studies showed that DONSON is a member of replisome complex and protected stalled or damaged replication forks. Also, DONSON interacted with several DNA replication factors and facilitated the activation of the intra‐S‐phase and G~2~/M cell cycle checkpoints.[29](#cas14327-bib-0029){ref-type="ref"} Minichromosome maintenance (*MCM*) proteins are crucial DNA replication genes that interact with DONSON. They are often overexpressed in ccRCC tissues and could be useful prognostic markers in ccRCC patients.[34](#cas14327-bib-0034){ref-type="ref"}, [35](#cas14327-bib-0035){ref-type="ref"} Aberrant expression of DONSON was observed in sunitinib‐treated ccRCC and silencing *DONSON* inhibited cell growth and induced apoptosis and cell cycle arrest in G~2~/M phase. Our GSEA data analysis revealed that the EMT pathway was significantly enriched in the DONSON high expression group. Previous reports showed that EMT‐associated genes were overrepresented in TKI‐resistant ccRCC tissues compared with pretreatment ccRCC tissues.[36](#cas14327-bib-0036){ref-type="ref"} Tyrosine kinase inhibitor‐resistant RCC cells promoted the activities of EMT‐related genes, indicating that EMT was involved in the mechanism of resistance to TKI.[36](#cas14327-bib-0036){ref-type="ref"} These findings might explain the aberrant expression of DONSON that was detected in sunitinib‐treated ccRCC tissues. Also, our data showed that *miR‐101‐5p* regulated the expression of several EMT‐related genes, indicating *miR‐101‐5p* might have a relation to resistance to TKI treatment.

Expression of *DONSON* was an independent strong prognostic marker (better than tumor stage or pathological grade) and was associated with ccRCC patient survival in a propensity score‐matched cohort. Aberrant expression of *DONSON* has serious effects on the prognosis of patients with ccRCC. However, elucidation of the molecular mechanism for controlling *DONSON* expression in ccRCC cells is not sufficient. Exploring the causes of overexpression of *DONSON* in ccRCC cells is an important issue. Recent studies showed that expression of circular RNAs in cancer cells have participated in oncogenesis.[37](#cas14327-bib-0037){ref-type="ref"}, [38](#cas14327-bib-0038){ref-type="ref"} Interestingly, overexpression of circ‐*DONSON* (derived from exon 3 to exon 8 of *DONSON* mRNA) was detected in gastric cancer and its aberrant expression promoted gastric cancer cell aggressiveness through initiated *SOX4* expression.[31](#cas14327-bib-0031){ref-type="ref"} The oncogenic roles of the circ‐*DONSON* in ccRCC cells need to be investigated in the future.

We searched genes/pathways in ccRCC cells that were mediated by *DONSON*. Interestingly, DNA replication, mismatch repair, nucleotide excision repair, and spliceosome pathways were identified as *miR‐101‐5p* regulatory pathways. Among these pathways, genes involved in the DNA replication pathway (*DNA2*, *POLE*, *REFC4*, *LIG1*, *POLD4*, *POLA2*, and *RNASEH2A*) predicted poor prognosis of ccRCC patients. The replisome is a complex molecular machine that comprises the DNA replication apparatus.[39](#cas14327-bib-0039){ref-type="ref"} The replisome unwinds double‐stranded DNA into single strands.[40](#cas14327-bib-0040){ref-type="ref"} These findings suggest that aberrantly expressed genes involved in the replisome affected ccRCC pathogenesis.

In conclusion, this is the first research to report that *miR‐101‐5p* acted as an antitumor miRNA in ccRCC cells. Several oncogenic targets regulated by *miR‐101‐5p* were closely involved with ccRCC pathogenesis. Moreover, we found that *DONSON* and replisome genes, which we identified from analyses of genes controlled by antitumor *miR‐101‐5p*, could be novel prognostic and therapeutic targets in ccRCC.
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